Use of granulocyte colony‐stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO‐AML 2004 and DB AML‐01-Reference-Cited by-同舟云学术

Use of granulocyte colony‐stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO‐AML 2004 and DB AML‐01

Published:2019-03-07 Issue:6 Volume:66 Page:e27701
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Løhmann Ditte J. A.¹^ORCID,Asdahl Peter H.²,Abrahamsson Jonas³,Ha Shau‐Yin⁴,Jónsson Ólafur G.⁵,Kaspers Gertjan J. L.⁶⁷⁸,Koskenvuo Minna⁹,Lausen Birgitte¹⁰,Moerloose Barbara¹¹,Palle Josefine¹²,Zeller Bernward¹³,Hasle Henrik¹

Affiliation:

1. Department of Pediatrics and Adolescent MedicineAarhus University Hospital Aarhus Denmark

2. Department of HematologyAarhus University Hospital Aarhus Denmark

3. Institution for Clinical SciencesDepartment of PediatricsQueen Silvia Children's Hospital Gothenburg Sweden

4. Department of PediatricsQueen Mary Hospital and Hong Kong Pediatric Hematology and Oncology Study Group (HKPHOSG) Hong Kong China

5. Department of PediatricsLandspitali University Hospital Reykjavik Iceland

6. Department of PediatricsVU University Medical Center Amsterdam The Netherlands

7. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

8. Dutch Childhood Oncology Group The Hague The Netherlands

9. Division of Hematology‐Oncology and Stem Cell TransplantationNew Children's Hospital, University of Helsinki and Helsinki University Hospital Helsinki Finland

10. Department of Pediatrics and Adolescent MedicineRigshospitaletUniversity of Copenhagen Copenhagen Denmark

11. Department of Pediatric Hematology‐Oncology and Stem Cell TransplantationGhent University Hospital Ghent Belgium

12. Department of Woman´s and Children´s HealthUppsala University Uppsala Sweden

13. Division of Pediatric and Adolescent MedicineOslo University Hospital Oslo Norway

Funder

Børnecancerfonden

Kræftens Bekæmpelse

Novo Nordisk Fonden

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27701

Reference27 articles.

1. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

2. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia

3. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

4. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

5. Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study Group

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis;Cancer Investigation;2024-06-26

2. An Interpretable Machine Learning Framework for Rare Disease: A Case Study to Stratify Infection Risk in Pediatric Leukemia;Journal of Clinical Medicine;2024-03-20

3. Infection Management in Pediatric AML;Pediatric Oncology;2024

4. Evidence for adverse effects by G-CSF in some acute lymphoblastic leukemias;Transfusion and Apheresis Science;2022-12

5. Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium;Expert Review of Anticancer Therapy;2022-10-28